Company intelligence / Profile preview

Elgan Pharma

Nazareth, Northern District, Israelelganpharma.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Elgan Pharma has two lead clinical programs. The first, ELGN-GI, promotes faster intestinal maturation in preterm infants to help them reach full enteral feeding and reduce complications. This program has completed several clinical trials including a successful Phase III study and recently started a second Phase III trial. The second program, ELGN-EYE, targets prevention of retinopathy of prematurity—a leading cause of childhood blindness—with a local drug therapy; it has successfully concluded a Phase I study with plans to begin Phase II shortly[1].

Therapeutic areas: GastroenterologyOphthalmology
Modalities: Small molecules (based on the description of non-invasive drug therapies for neonates)
Industry: Biotech

Drug pipeline

2 assets

elgn-gi

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Elgan Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elgan Pharma.

Explore the full profile